Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-16

Animal models and drug design for therapy of cancers induced by the oncogene, met

Objective

Cancer is among the most devastating human diseases and a major aim of the biomedical research is to develop anti-neoplastic molecularly targeted therapies. Receptor tyrosine kinases (RTKs) are pivotal targets for anti-cancer therapies because deregulated RTK signals underlie most events of tumour growth, angiogenesis and metastasis. Strategies to block aberrant RTK signalling involve the development of small chemical compounds that selectively interfere with receptor activation. The RTK Met is a prognostic marker for different carcinomas. Its hyperactivity is thought to be a key event into the development of the invasive/metastatic phenotype of neoplastic cells. The aim of this proposal is to develop Met-specific anticancer drugs. First, a collection of pot ential Met chemical inhibitors will be synthesized and tested for their ability of blocking Met-mediated cell scattering in vitro and activation of its downstream signal transducers. In addition, the first genetically defined animal model of Met-mediated t umour and metastasis will be generated by over-expressing Met only in specific cell types (CRE-mediated recombination). These cells will also express the Luciferase gene allowing non-invasive monitoring of primary tumours and metastasis in vivo. Finally, t his novel mouse strain will be used to optimise the in vivo responses of Met-induced cancers to candidate Met inhibitors. One of the main driving forces of this project is the multi-disciplinary approach undertaken to tackle problems of human health like c ancer. Given the complexity of the cancer biology many researchers with different intellectual and technical skills, ranging from chemical to biology, molecular to in vivo, genetics to pathology will converge. This novel research team will lead this propos al to achieve scientific goals that are at the cutting edge of cancer research, and will potentially set new trends to establish European research as having a world-leading role in this field.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP6-2002-MOBILITY-3
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

TOK - Marie Curie actions-Transfer of Knowledge

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
EU contribution
No data
Address
101 Rue de Tolbiac
PARIS
France

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0